HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study
These findings suggest that HTD1801 has strong potential to produce histological improvements in patients with MASH.
Authors
- Ru Bai
- Adrian M. Di Bisceglie (ORCID: https://orcid.org/0000-0002-6075-9305)
- Nadege Gunn (ORCID: https://orcid.org/0000-0003-3118-3690)
- A. Sender Liberman (ORCID: https://orcid.org/0000-0002-4494-4834)
- Junwei Cheng (ORCID: https://orcid.org/0000-0003-3159-5222)
- Liping Liu (ORCID: https://orcid.org/0000-0001-6356-0978)
- Vincent Wai‐Sun Wong (ORCID: https://orcid.org/0000-0003-2215-9410)
- Yu Meng (ORCID: https://orcid.org/0000-0003-3258-1105)
- Guy Neff
Institutions
- Chinese University of Hong Kong (HK)
- Sino Biopharmaceutical (China) (CN)
- Carolina Veterinary Specialists (US)
- Velocity Clinical Research (United States) (US)
- Celldex Therapeutics (United States) (US)
Publication Details
- Journal
- Clinical and Molecular Hepatology
- Published
- 2025-04-21
- DOI
- https://doi.org/10.3350/cmh.2025.0145
- Citations
- 7
- Primary Topic
- Radiomics and Machine Learning in Medical Imaging
- Type
- article
- Field-Weighted Citation Impact
- 9.52
Funders
- Zhejiang Chinese Medical University